幽门螺杆菌感染与胃癌化疗疗效的关系

Helicobacter pylori infection and chemotherapy sensitivity in gastric cancer

目的:探讨幽门螺杆菌(Helicobacter pylori,H.pylori)与胃癌化疗敏感性的关系,为胃癌化疗患者是否要进行根除H.pylori治疗提供理论依据.方法:选取近5年我科被确诊为胃癌且由于各种原因未行手术治疗而选择化疗的H.pylori阳性患者240例,根据是否给予根除H.pylori治疗将其分为观察组和对照组,两个疗程之后对化疗疗效进行评定,分析H.pylori与胃癌化疗敏感性的关系,寻找其内在规律.结果:观察组疗效优于对照组,差别有统计学意义;观察组中虽经根除H.pylori治疗,根除组与未被根除组比较,疗效前者优于后者,差别有统计学意义;未被根除组与未给予根除组比较,疗效后者优于前者,但差别无统计学意义.结论:根除H.pylori可提高胃癌化疗的敏感性.

AIM： To investigate the relationship between Helicobacter pylori （H. pylori） infection and chemotherapy sensitivity in gastric cancer to provide a theoretical basis for H. pylori eradication therapy in gastric cancer patients undergoing chemotherapy. METHODS： Two hundred and forty H. pylori positive patients with gastric cancer who did not undergo surgery for various reasons but received chemotherapy in recent five years at our hospital were included in this study. Based on whether to receive H. pylori eradication therapy, they were divided into an observation group and a control group. After two cycles of chemotherapy, they were evaluated to analyze the relationship between H. pylori infection and chemotherapy sensitivity. RESULTS： The curative effect was significantly better in the observation group than in the control group. In the observation group, the curative effect was significantly better in the eradicated group than in the non-eradicated group. The curative effect was better in the non-eradicated group than in the control group, but the difference was not statistically significant. CONCLUSION： The eradication of H. pylori can improve chemotherapy sensitivity in patients with gastric cancer.